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Introduction: Despite the advances in radiation techniques and che-
motherapy, survival with current platinum-based chemotherapy and 
concomitant thoracic radiation remains dismal. Bortezomib, a pro-
teasome inhibitor, modulates apoptosis and cell cycle through dis-
ruption of protein degradation. The combination of bortezomib and 
carboplatin/paclitaxel and concurrent radiation in unresectable stage 
III non–small-cell lung cancer was evaluated in this phase I/II study.
Methods: Patients with histologic or cytologic confirmed stage III non-
metastatic non–small-cell lung cancer who were candidates for radiation 
therapy were eligible. In the phase I portion, patients received escalating 
doses of bortezomib, paclitaxel, and carboplatin concomitantly with tho-
racic radiation (60 Gy/30 daily fractions) using a modified 3 + 3 design. 
The primary endpoint for the phase II portion was the 12-month survival 
rate (12MS). A one-stage design with an interim analysis yielded 81% 
power to detect a true 12MS of 75%, with a 0.09 level of significance if 
the true 12MS was 60% using a sample size of 60 patients. Secondary 
endpoints consisted of adverse events (AEs), overall survival, progres-
sion-free survival, and the confirmed response rate.
Results: Thirty-one patients enrolled during the phase I portion of the 
trial, of which four cancelled before receiving treatment, leaving 27 
evaluable patients. Of these 27 patients, two dose-limiting toxicities 
were observed, one (grade 3 pneumonitis) at dose level 1 (bortezo-
mib at 0.5 mg/m2, paclitaxel at 150 mg/m2, and carboplatin at area 
under the curve of 5) and one (grade 4 neutropenia lasting ≥8 days) 
at dose level 6 (bortezomib 1.2 mg/m2, paclitaxel 175 mg/m2, and car-
boplatin at area under the curve of 6). During the phase I portion, the 
most common grade 3 of 4 AEs were leukopenia (44%), neutrope-
nia (37%), dyspnea (22%), and dysphagia (11%). Dose level 6 was 
declared to be the recommended phase II dose (RP2D) and the phase 
II portion of the study opened. After the first 26 evaluable patients 
were enrolled to the RP2D, a per protocol interim analysis occurred. 
Of these 26 patients, 23 (88%) survived at least 6 months (95% con-
fidence interval [CI], 70–98%), which was enough to continue to full 
accrual per study design. However, due to slow accrual, the study 
was stopped after 27 evaluable patients were enrolled (6—phase I 
RP2D; 21—phase II). Of these 27 patients, the 12MS was 73% (95% 
CI, 58–92%), the median overall survival was 25.0 months (95% CI, 
15.6–35.8), and the median progression-free survival was 8.4 months 
(95% CI, 4.1–10.5). The confirmed response rate was 26% (seven of 
27; 95% CI, 11–46%), consisting of four partial responses and three 
complete responses. Grade 3+ and grade 4+ AEs occurred in 82% 
and 56% of patients, respectively. One patient experienced grade 5 
pneumonitis that was possibly related to the treatment. Grade 3 and 
4 hematological toxicities were observed in 82% and 56% patients, 
respectively.
Conclusions: The addition of bortezomib to concurrent carboplatin/
paclitaxel and radiation seemed to be feasible, although associated 
with increased hematological toxicities. A favorable median overall 
survival of 25 months suggests a potential benefit for this regimen.
(J Thorac Oncol. 2015;10: 172–180)
Lung cancer is the most common cause of cancer deaths in the United States with an estimated mortality of 159,480 
in 2013.1 Non–small-cell lung cancer (NSCLC) accounts for 
approximately 85% to 90% of lung cancer diagnoses. Only 
25% to 30% of patients with NSCLC have early stage and 
localized disease that is resectable (stage I or II) at the time of 
diagnosis.2 For the 30% of patients with regionally advanced, 
DOI: 10.1097/JTO.0000000000000383 
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1001-0172
A Phase I/II Study of Bortezomib in Combination with 
Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation 
Therapy for Non–Small-Cell Lung Cancer
North Central Cancer Treatment Group (NCCTG)-N0321
Yujie Zhao, MD, PhD,* Nathan R. Foster, MS,† Jeffrey P. Meyers, BA,† Sachdev P. Thomas, MD,‡  
Donald W. Northfelt, MD,§ Kendrith M. Rowland Jr., MD,║ Bassam I. Mattar, MD,¶  
David B. Johnson, MD,¶ Julian R. Molina, MD, PhD,# Sumithra J. Mandrekar, PhD,† Steven E. Schild, MD,**  
James D. Bearden III, MD,†† Marie-Christine Aubry, MD,‡‡ and Alex A. Adjei, MD, PhD*
*Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; 
†Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; 
‡Illinois CancerCare, Peoria, IL; §Hematology/Oncology and **Radiation 
Oncology, Mayo Clinic, Scottsdale, AZ; ║Carle Cancer Center Community 
Clinical Oncology Program, Urbana, IL; ¶Wichita Community Clinical 
Oncology Program, Wichita, KS; #Oncology and ‡‡Laboratory Medicine 
and Pathology, and Anatomic Pathology, Mayo Clinic, Rochester, MN; and 
††Upstate Carolina CCOP, Spartanburg, SC.
The study was also supported, in part, by grants from the National Cancer 
Institute (CA31946) to the Alliance for Clinical Trials in Oncology 
(Monica M. Bertagnolli, MD) and to the Alliance Statistics and Data 
Center (Daniel J. Sargent, PhD, CA33601).
The remaining authors have no funding or conflicts of interest to disclose.
Address for correspondence: Alex A. Adjei, MD, PhD, Roswell Park Cancer 
Institute, Elm & Carlton Streets, Buffalo, NY 14263. E-mail: Alex.
Adjei@RoswellPark.org
ORIGINAL ARTICLE
173Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015 Bortezomib, Paclitaxel, Carboplatin, and Concurrent Radiation in NSCLC
inoperable disease, the recommended therapeutic approach is 
combined modality therapy with thoracic radiation therapy 
(RT) and chemotherapy.3–6 Despite the advances in irradiation 
techniques and improved chemotherapy, local and distant con-
trol remain suboptimal, and the majority of patients continue 
to die from distant metastases.5,7–10 To improve efficacy of this 
treatment approach, chemoradiotherapy incorporating novel 
molecular targeting agents is being actively investigated.
Bortezomib (VELCADE, PS-341) is a dipeptide boronic 
acid analogue that reversibly inhibits the 26S proteasome, a 
large protease complex that degrades ubiquitinated proteins. 
By blocking proteolysis, bortezomib leads to accumulation of 
proteins involved in multiple signal transduction pathways, 
resulting in cell cycle arrest, apoptosis and down-regulation of 
angiogenesis. For example, it stabilizes the cyclin-dependent 
kinase inhibitors p21 and p27 and blocks cell division in the 
G
2
-M phase of the cell cycle. It inhibits the degradation of 
the wild-type tumor suppressor protein p53 and suppresses 
the activation of oncogene nuclear factor (NF)-κB. It inhibits 
overexpression of antiapoptotic protein B-cell lymphoma 2 
and favorably modulates apoptosis.11–14
Bortezomib has been approved for the treatment of 
multiple myeloma and mantle cell non-Hodgkin’s lymphoma. 
In NSCLC, bortezomib has been combined with docetaxel, 
pemetrexed, gemcitabine/carboplatin, carboplatin/bevaci-
zumab, vorinostat, and erlotinib in clinical studies with various 
levels of activity observed.15–21 In a phase I study combining 
bortezomib and carboplatin/paclitaxel, the maximum tolerated 
dose (MTD) and the recommended phase II dose (RP2D) was 
found to be bortezomib 1.2 mg/m2, paclitaxel 175 mg/m2 and 
carboplatin at area under the curve (AUC) of 6, and a schedule 
of bortezomib given on days 1, 4, and 8 followed by paclitaxel 
and carboplatin on day 2 every 21 days was found to be more 
efficacious than when paclitaxel and carboplatin were given on 
day 1 of each cycle.22 Furthermore, bortezomib was found to be 
synergistic with radiotherapy in vitro and in animal models.23 
In a 12-patient phase I study evaluating carboplatin/paclitaxel/
bortezomib and concurrent radiotherapy as induction therapy 
followed by surgical resection in stage III non–small-cell lung 
cancer, five patients achieved complete pathologic response 
and two other patients were found to have necrosis occurred 
in 99% of tumor tissue.24 Here, we report a phase I/II study 
evaluating carboplatin/paclitaxel/bortezomib in combination 
with concurrent radiation as primary definitive treatment for 
patients with unresectable local regionally advanced NSCLC.
PATIENTS AND METHODS
Eligibility Criteria
Patients with histologic or cytologic confirmed inoper-
able nonmetastatic (stage IIIA or IIIB according to American 
Joint Committee on Cancer staging system 6th edition) 
non–small-cell lung carcinoma (NSCLC) requiring RT were 
eligible for the study. Other eligibility criteria included the fol-
lowing: aged 18 years or older; Eastern Cooperative Oncology 
Group performance status (ECOG PS) ≤1; life expectancy of 
12 weeks or longer; absolute neutrophil count ≥1.5 × 109/liter; 
platelet count ≥100 × 109/liter; total serum bilirubin ≤1.5 mg/dl 
or direct bilirubin ≤1.5 × upper limits of normal (ULN); and 
aspartate transaminase ≤3 ×ULN and creatinine ≤1.5 ×ULN. 
Patients with weight loss of 10% or greater in past 3 months, 
forced expiratory volume in 1 second less than 1 liter or 35% 
of predicted forced expiratory volume in 1 second, history 
of before RT to the chest and systemic chemotherapy for 
NSCLC, major surgery or unhealed wound ≤2 weeks before 
registration, New York Heart Association classification III or 
IV, uncontrolled infection, and peripheral neuropathy ≥ grade 
2 were excluded. Written informed consent approved by insti-
tutional review boards and the National Cancer Institute were 
obtained from eligible patients before prestudy assessments.
Study Design
This was a multicenter co-operative group, open-label, 
single-arm, combined phase I dose-escalation, and phase II 
study to assess the safety, tolerability, and efficacy of carbo-
platin/paclitaxel/bortezomib and concurrent daily thoracic RT 
in advanced nonmetastatic NSCLC. Patients received esca-
lating doses of carboplatin/paclitaxel/bortezomib, up to the 
RP2D recommended in a previous phase I study evaluating 
this combination.22 After determination of RP2D, additional 
patients were enrolled for the phase II part of the study.
Eligible patients received treatment in an outpatient set-
ting with chemotherapy and radiotherapy concurrently deliv-
ered over a 6-week period. Complete blood cell counts were 
obtained weekly during periods of active study treatment, at 4 
weeks postradiation, and at each post-treatment follow-up visit. 
Serum chemistries were collected before each cycle of che-
motherapy and at each post-treatment follow-up visit. A chest 
computed tomography was performed at baseline, 4 weeks post-
radiation, 3 months postradiation, and then every 3 months for 
1 year, followed by computed tomography every 6 months for a 
maximum of 5 years from the time of registration. Full support-
ive care, including blood-product support, antibiotic treatment, 
antidiarrheals, analgesics, antiemetics, and medications used 
for the prevention and treatment of radiation esophagitis, nutri-
tional evaluation, and treatment of other newly diagnosed or 
concurrent medical conditions was provided. Prophylactic use 
of colony-stimulating factors during the study was not allowed. 
Therapeutic use of colony-stimulating factors in patients with 
serious neutropenic complications, such as tissue infection, 
sepsis syndrome, fungal infection, and so on, was allowed at the 
investigator’s discretion. Recombinant erythropoietin to main-
tain adequate hemoglobin levels and avoid packed red blood 
cell transfusions was allowed.
Chemotherapy
Bortezomib was administered by intravenous push 
on days 1, 4, 8, and 11 of each 21-day cycle. Paclitaxel was 
administered intravenously over 3 hours on day 2 of each 
cycle. Carboplatin was administered as a 30-minute intrave-
nous infusion immediately after paclitaxel infusion on day 2 of 
each cycle. Thirty minutes before the paclitaxel dose, patients 
were premedicated with 10 to 20 mg dexamethasone intrave-
nously or orally, 25 to 50 mg diphenhydramine HCl intrave-
nously, and 50 mg ranitidine or 300 mg cimetidine or 20 mg 
famotidine intravenously. Bactrim 1 tablet twice daily was 
administered twice per week continuously during treatment.
174 Copyright © 2014 by the International Association for the Study of Lung Cancer
Zhao et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
In the phase I part, groups of three to six patients were 
entered at different dose levels after the dose escalation 
scheme given in Table 1. In the phase II part, bortezomib at 
1.2 mg/m2, paclitaxel at 175 mg/m2, and carboplatin at AUC of 
6 were administered.
Radiation Therapy
RT administering 2 Gy once daily began on day 1 
of chemotherapy for all patients. Three-dimensional radio-
therapy with no inhomogeneity corrections was used. 
Intensity modulated radiotherapy was not allowed. Elective 
nodal irradiation was administered for the first 42 to 44 
Gy. The primary tumor, mediastinum, and ipsilateral hilum 
were covered with a 2-cm margin to block edge. The mini-
mal mediastinal volume superiorly to inferiorly extended 
from the top of T1 superiorly to 5 cm below the carina infe-
riorly. Elective inclusion of the supraclavicular fossa was 
allowed at the discretion of the treating physician. If supra-
clavicular disease was present, both fossae were treated. 
After 42 to 44 Gy was given, off-cord oblique fields treated 
gross disease (primary tumor and enlarged lymph nodes 
(>1 cm in short diameter)) with 2 cm margins between the 
tumor and block edge. A total dose of 60 Gy was delivered 
to the isocenter in 30 fractions given 5 days per week at 2 
Gy daily. The spinal cord was limited to a maximum dose 
of 48 Gy. The total lung volume receiving 20 Gy or greater 
was limited to 40% or less. One-third of the heart could 
not receive greater than 60 Gy, two-third of the heart could 
not receive more than 50 Gy, and the entire heart could not 
receive more than 40 Gy.
Response and Toxicity Criteria
All toxicities were graded using National Cancer 
Institute Common Terminology Criteria for Adverse Events 
version 3.0 (before December 31, 2010) or Common 
Terminology Criteria for Adverse Events version 4.0 (after 
January 1, 2011). Assessment of disease response occurred 
4 weeks postradiotherapy, 3 months postradiotherapy, every 
3 months for 1 year postradiotherapy, and every 6 months 
thereafter for a maximum of 5 years from time of registration. 
Treatment response was evaluated using Response Evaluation 
Criteria in Solid Tumors criteria.25
End Points and Statistical Analysis
The primary endpoint of the phase I portion was the 
MTD of the treatment combination using a modified cohort 
of three design,26 where the MTD was defined as the highest 
safely tolerated dose where at most two of six patients expe-
rienced a dose-limiting toxicity (DLT), with the next higher 
dose level having at least three of six patients with a DLT. Any 
of the following were considered DLTs over the 6 weeks of 
combined chemotherapy/RT, including a 4-week observation, 
where the DLT needed to be possibly, probably, or definitely 
related to study treatment: grade 4 radiation dermatitis, grade 
4 neutropenia or thrombocytopenia lasting at least 8 days or 
grade 4 febrile neutropenia (first 3 weeks of chemotherapy 
only for hematologic DLTs), grade ≥3 esophagitis requir-
ing hospitalization, grade ≥3 pneumonitis requiring oxygen, 
grade 4 dyspnea at rest, and other nonhematologic grade 4 
toxicities not manageable with medical interventions (intra-
venous, narcotic). If the study did not reach the MTD by dose 
level 6 (Table 1), dose level 6 would be considered the RP2D.
The primary endpoint of the phase II portion of the study 
was 12-month survival, where all patients enrolled at the MTD 
(or RP2D) would be included in the analysis. The 12-month 
survival rate was calculated using Kaplan–Meier methodol-
ogy.27 A one-stage design with an interim analysis was used 
to test whether there was sufficient evidence to determine that 
the 12-month survival rate was at least 75% (i.e., clinically 
promising) versus at most 60% (i.e., clinically inactive). After 
the first 26 evaluable patients had been on-study for 6 months, 
an interim analysis was performed. At least 21 of these 26 
patients surviving greater than or equal to 6 months postreg-
istration would be considered sufficient activity to continue to 
full accrual. Otherwise, the study would be stopped early for 
lack of efficacy. At least 41 of all 60 (68%) evaluable patients 
surviving greater than or equal to 12 months postregistration 
would be considered adequate evidence of promising activity 
and would warrant further testing of this regimen in subse-
quent studies. This design yielded 81% power to detect a true 
12-month survival rate of 75%, with a 0.09 level of signifi-
cance if the true 12-month survival rate was 60%.
Secondary end points were adverse event rates, overall 
survival (defined as the time from registration to death due to 
any cause), progression-free survival (defined to be the length 
of time from study registration to the first of either disease pro-
gression or death due to any cause), confirmed tumor response 
(defined to be a complete response or partial response noted as 
the objective status on two consecutive evaluations at least 4 
weeks apart), and treatment tolerability. The maximum grade 
for each type of adverse event was recorded for each patient, 
and frequency tables were used to determine adverse event 
patterns for both phases of the study (regardless of attribution 
to the study treatment). The commonly occurring grade 3 and 
greater adverse events (>5%) were also reported, including all 
grade 4 or higher adverse events. Kaplan–Meier methodol-
ogy was used to estimate the distributions of overall survival 
and progression-free survival27 for the RP2D patients only. 
The confirmed response rate was estimated by the number of 
patients who had documented confirmed responses (PR or CR 
maintained for a minimum of 4 weeks) divided by the total 
TABLE 1.  Dose Escalation Scheme
Dose  
Level
Bortezomib 
(mg/m2)
Paclitaxel 
(mg/m2)
Carboplatin 
AUC
−1 0.5 120 5
0 0.5 135 5
1a 0.5 150 5
2 0.8 150 5
3 1.0 150 5
4 1.0 175 5
5 1.0 175 6
6 1.2 175 6
aStarting dose level.
AUC, area under the curve.
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number of evaluable patients for the RP2D patients only. All 
patients who were eligible and started treatment were evalu-
able for all primary and secondary endpoints in this study. 
All analyses were conducted using SAS version 9.3 on data 
available as of March 18, 2014. Data collection and statistical 
analyses were conducted by the Alliance Statistics and Data 
Center. Data quality was ensured by review of data by the 
Alliance Statistics and Data Center and by the study chairper-
son following Alliance policies.
RESULTS
Radiation Therapy Quality Assessment
RT plans and port films were reviewed for all 48 
patients. These were reviewed in detail by two NCCTG inves-
tigators and one Radiologic Physics Center reviewer based on 
protocol specified criteria. There were 44 (92%) patients with 
no deviations, three (6%) had minor deviations and one (2%) 
had a major deviation.
Patient Characteristics and Reasons  
Off Treatment
Phase I
Thirty-one patients with locally advanced stage IIIA 
or IIIB NSCLC were enrolled into the phase I portion of the 
trial from April 25, 2005, to July 13, 2009, of which 27 were 
deemed evaluable because four patients withdrew before 
receiving treatment. Patients were enrolled to a total of six 
dose levels (Table 1), where dose level 6 was the dose selected 
for the phase II portion of the study (Table 2 Consolidated 
Standards of Reporting Trials [CONSORT] diagram for fur-
ther details). The characteristics of the phase I patients are 
summarized in Table 3. The median age of the 27 patients was 
63 years (range, 45–78). Seventeen (63%) patients were men 
and 10 (37%) patients were women. Approximately 33% of 
patients presented with stage IIIA disease, whereas 67% of 
patients presented with stage IIIB disease. Fifteen patients 
(56%) had an ECOG PS of 0, and 12 patients (44%) had an 
ECOG PS of 1 (Table 3). All patients ended active treatment, 
with most completing the study per protocol (17/27; 63%). 
Of the other 10 patients, five went off treatment early due to 
adverse events, three went off treatment due to disease pro-
gression, and two went off treatment for other reasons.
Phase II (RP2D)
Only 21 patients were enrolled to the phase II portion 
because the study was closed early due to slow accrual. In addi-
tion, seven patients were enrolled at the recommended phase II 
dose (RP2D) during the phase I portion (dose level 6). These 28 
patients were enrolled from July 31, 2008 to January 14, 2011. 
Of the 28 patients enrolled, 27 were deemed evaluable because 
one patient withdrew before receiving treatment (Table 2 the 
CONSORT diagram for further details). There were 17 (63%) 
men and 10 (34%) women, with a median age of 58 years 
(range, 43–79). Approximately 48% of patients presented with 
stage IIIA disease, whereas 52% of patients had stage IIIB dis-
ease. Nine patients (33%) had a baseline ECOG PS of 0, and 
18 patients (67%) had an ECOG PS of 1 (Table 3). All patients 
have ended active treatment. Approximately 67% (18 of 27) of 
patients completed the entire protocol treatment. Among the 
nine patients who ended treatment early, 4 (44%) discontinued 
treatment due to adverse events, 2 (22%) discontinued treat-
ment due to disease progression, 1 (11%) patient refused fur-
ther treatment, and the other 2 (22%) went off for other reasons.
Tolerability and Toxicity
Phase I
Twenty-seven patients were evaluable for adverse 
events across the six phase I dose levels (Table 4). Dose level 
1 resulted in one of six patients experiencing a DLT (grade 
3 pneumonitis requiring oxygen). Although no patients expe-
rienced a DLT per protocol for dose levels 2 to 5, we did 
enroll six patients at dose level 3 because one of the first three 
patients went off treatment early due to adverse events. Dose 
level 6 enrolled six evaluable patients with only one patient 
experiencing a DLT (grade 4 neutropenia lasting ≥8 days). 
Dose level 6 (bortezomib: 1.2 mg/m2; paclitaxel: 175 mg/m2; 
carboplatin: AUC of 6 for 2 cycles with concurrent radiation) 
was chosen as the RP2D because we went through all 6 dose 
TABLE 2.   Consort Diagram
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levels without reaching the MTD. Overall, 20 of 27 patients 
(74%) experienced grade 3 of 4 adverse events (regardless of 
attribution), and 11 of 27 (41%) experienced grade 4 adverse 
events (Table 4). No grade 5 adverse events occurred. The 
most commonly occurring grade 3 of 4 adverse events (fre-
quency, %) consisted of leukopenia (12, 44%), neutropenia 
(10, 37%), dyspnea (6, 22%), and dysphagia (3, 11%). All 
commonly occurring grade 3 of 4 adverse events (>5%) are 
shown in Table 5, including all grade 4 adverse events.
Phase II (RP2D)
Twenty-seven patients were evaluable for adverse 
events in the phase II portion of the study (Tables 4 and 5). 
Although dose reductions were needed at times, most patients 
received the majority of the doses, as shown in Table 6 for 
the patients enrolled at the recommended phase II dose. 
Twenty-two of these 27 patients (82%) experienced at least 
one grade 3 or worse adverse event (regardless of attribu-
tion). In addition, 15 (56%) patients experienced at least one 
grade 4 or worse adverse event, including one patient with a 
grade 5 adverse event (pneumonitis that was possibly related 
to treatment) (Table 4). The most commonly occurring grade 
3 adverse events (frequency, %) consisted of leukopenia (13, 
48%), neutropenia (12, 44%), fatigue (6, 22%), and nausea 
(3, 11%) (Table 5). The most commonly occurring grade 4 
adverse events (frequency, %) were all hematologic and con-
sisted of thrombocytopenia (10, 37%), neutropenia (6, 22%), 
and leukopenia (4, 15%) (Table 5). Nonhematologic grade 4 
adverse events (frequency, %) consisted of dyspnea (1, 4%), 
depressed level of consciousness (1, 4%), myalgia (1, 4%), 
TABLE 3.  Baseline Demographics
Phase 1 Dose Levels Combined Phase
1  
(n = 6)
2  
(n = 3)
3  
(n = 6)
4  
(n = 3)
5  
(n = 3)
6a  
(n = 6)
Phase 1  
(n = 27)
Phase II RP2Db  
(n = 27)
Age
  Median 58.5 70.0 61.0 75.0 68.0 55.5 63.0 58.0
  Range (55.0–78.0) (68.0–76.0) (55.0–68.0) (45.0–78.0) (63.0–70.0) (47.0–65.0) (45.0–78.0) (43.0–79.0)
Gender
  Female 2 (33.3%) 1 (33.3%) 1 (16.7%) 3 (100.0%) 1 (33.3%) 2 (33.3%) 10 (37.0%) 10 (37.0%)
  Male 4 (66.7%) 2 (66.7%) 5 (83.3%) 0 (0.0%) 2 (66.7%) 4 (66.7%) 17 (63.0%) 17 (63.0%)
Tumor stage
  IIIA 1 (16.7%) 1 (33.3%) 0 (0.0%) 1 (33.3%) 2 (66.7%) 4 (66.7%) 9 (33.3%) 13 (48.1%)
  IIIB 4 (66.7%) 1 (33.3%) 6 (100.0%) 2 (66.7%) 1 (33.3%) 0 (0.0%) 14 (51.9%) 11 (40.7%)
  IIIB with 
pleural 
effusion
1 (16.7%) 1 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (33.3%) 4 (14.8%) 3 (11.1%)
N-stage
  N1 1 (20.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 2 (7.7%) 4 (14.8%)
  N2 1 (20.0%) 2 (66.7%) 2 (33.3%) 2 (66.7%) 2 (66.7%) 5 (83.3%) 14 (53.8%) 16 (59.3%)
  N3 3 (60.0%) 1 (33.3%) 4 (66.7%) 1 (33.3%) 1 (33.3%) 0 (0.0%) 10 (38.5%) 7 (25.9%)
ECOG PS
  0 5 (83.3%) 1 (33.3%) 3 (50.0%) 2 (66.7%) 2 (66.7%) 2 (33.3%) 15 (55.6%) 9 (33.3%)
  1 1 (16.7%) 2 (66.7%) 3 (50.0%) 1 (33.3%) 1 (33.3%) 4 (66.7%) 12 (44.4%) 18 (66.7%)
Pretreatment supraclavicular involvement
  Yes 3 (50.0%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 1 (33.3%) 1 (16.7%) 6 (22.2%) 4 (14.8%)
  No 3 (50.0%) 3 (100.0%) 5 (83.3%) 3 (100.0%) 2 (66.7%) 5 (83.3%) 21 (77.8%) 23 (85.2%)
Maximum pretreatment tumor size (cm)
  <3 0 (0.0%) 1 (33.3%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 3 (11.1%) 4 (14.8%)
  3–6 4 (66.7%) 2 (66.7%) 1 (16.7%) 3 (100.0%) 2 (66.7%) 3 (50.0%) 15 (55.6%) 15 (55.6%)
  >6 2 (33.3%) 0 (0.0%) 4 (66.7%) 0 (0.0%) 1 (33.3%) 2 (33.3%) 9 (33.3%) 8 (29.6%)
Weight loss past 3 months
  <5% 3 (50.0%) 3 (100.0%) 5 (83.3%) 3 (100.0%) 3 (100.0%) 5 (83.3%) 22 (81.5%) 22 (81.5%)
  5–10% 3 (50.0%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 5 (18.5%) 5 (18.5%)
Diabetes
  No diabetes 4 (66.7%) 3 (100.0%) 6 (100.0%) 3 (100.0%) 3 (100.0%) 6 (100.0%) 25 (92.6%) 26 (96.3%)
  Type II 2 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (7.4%) 1 (3.7%)
aIncluded in phase II analysis.
bThe recommended phase II dose (RP2D) included six phase I patients enrolled at dose level 6 and 21 patients enrolled during the phase II portion only.
ECOG PS, Eastern Cooperative Oncology Group performance status.
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serum sodium decrease (1, 4%), serum potassium decrease (1, 
4%), and hypoxia (1, 4%). All commonly occurring grade 3 
of 4 adverse events (>5%) are shown in Table 5, including all 
grade 4 adverse events.
Response and Survival of 
Phase II Portion (RP2D)
A per protocol interim analysis occurred after the first 
26 evaluable patients were enrolled. Of these 26 patients, 23 
(88%) survived at least 6 months (95% confidence interval 
[CI], 70–98%), which was enough to continue to full accrual 
per study design. However, due to slow accrual, the study was 
stopped after 27 evaluable patients were enrolled (6—phase I 
RP2D; 21—phase II). All 27 patients were evaluable for the 
outcome measures of survival, progression-free survival, and 
confirmed response. Of all 27 patients, 17 (63%) have died, and 
the median follow-up time was 26.9 months (range, 5.7–56.7) 
for the 10 patients who were still alive. The 12-month sur-
vival rate was 73% (95% CI, 58–92%). The median survival 
(Fig. 1) was 25.0 months (95% CI, 15.6–35.8 months), and 
the median progression-free survival (Fig. 2) was 8.4 months 
(95% CI, 4.1–10.5 months). The confirmed response rate was 
26% (seven of 27; 95% CI, 11–46%), which consisted of four 
partial responses (15%) and three complete responses (11%). 
Clinical benefit rate (stable disease [10 patients] + confirmed 
responses [seven patients]) was 63% (95% CI, 42–81%).
DISCUSSION
When administered concurrently with thoracic radiation, 
chemotherapy can sensitize tumor cells to radiation, and ulti-
mately improve the local control and survival in advanced non-
metastatic NSCLC. However, despite the successful application 
of chemoradiotherapy, the survival rate remains dismal. Novel 
targeting therapeutic agents, including bevacizumab, erlotinib, 
gefitinib, and cetuximab, have been tested in combination 
with thoracic radiation in clinical studies.28–32 The incorpora-
tion of the proteasome inhibitor bortezomib has the presumed 
advantages of disrupting signal transduction pathways that are 
responsible for radio-resistance, such as activation of NF-κB,33 
loss of p5334,35 and overexpression of B-cell lymphoma 2,36 and 
promoting radiation sensitivity by accumulating cells in the 
radiosensitive G2 and M phases,37,38 therefore representing a 
promising strategy. Despite early termination of the study due 
to slow accrual, a promising 12-month survival of 73% and an 
impressive median overall survival of about 25 months were 
observed in this small study, which seems to be much higher 
than the overall survival reported with other chemotherapy 
regimens.5,39,40 In two phase II studies evaluating weekly carbo-
platin/paclitaxel and concurrent thoracic radiotherapy (regular 
fractions or hyperfractionated) followed by two cycles of con-
solidative carboplatin/paclitaxel chemotherapy, LUN-56 and 
LUN-63, the median length of overall survival was 17.4 and 
14 months, respectively,41 and the 12-month survival rates were 
56% and 61%, respectively.42 When compared with historical 
data, our results suggested a potential survival benefit associ-
ated with the addition of bortezomib and this approach war-
rants further investigation.
When compared with other concurrent chemotherapy 
regimens, a much higher rate of grade 3 (82%) and 4 (56%) 
hematological adverse events were observed in the phase II 
portion of this study.5,8,43 Because hematological toxicities, 
especially thrombocytopenia, are common toxicities of bort-
ezomib,44 the significant bone marrow suppression observed 
with this regimen was not unexpected. However, the overlap-
ping toxicity profile of bortezomib and cytotoxic chemother-
apy may render this regimen less tolerable and limit its usage.
Despite the success in the treatment of hematological 
malignancies, the activity of bortezomib in solid tumors, includ-
ing NSCLC, overall has been less encouraging. Identification 
of patients who will likely gain benefit from the addition of 
bortezomib is essential. Moreover, because increased toxicities 
were observed with this regimen in comparison with histori-
cal data, proper selection of patients will be particularly impor-
tant to avoid unnecessary exposure to toxicities. In mantle cell 
lymphoma, patients with tumors that had low level proteasome 
(prosome, macropain) subunit, alpha type 5 expression, or 
higher NF-κB p65 expression seemed more likely to benefit 
from the addition of bortezomib as reported in the PINNACLE 
study, a phase II study comparing rituximab with and without 
TABLE 4.  Adverse Eventa Summary
Phase 1 Dose Levels Combined Phase
1  
(n = 6)
2  
(n = 3)
3  
(n = 6)
4  
(n = 3)
5  
(n = 3)
6b  
(n = 6)
Phase 1  
(n = 27)
Phase II RP2Dc,d  
(n = 27)
DLT (%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (16.7%) 2 (7.4%) 1 (3.7%)
Grade 3+ overall 5 (83.3%) 3 (100.0%) 4 (66.7%) 2 (66.7%) 2 (66.7%) 4 (66.7%) 20 (74.1%) 22 (81.5%)
Grade 4+ overall 4 (66.7%) 2 (66.7%) 1 (16.7%) 1 (33.3%) 0 (0.0%) 3 (50.0%) 11 (40.7%) 15 (55.6%)
Grade 3+ heme 3 (50.0%) 1 (33.3%) 2 (33.3%) 2 (66.7%) 2 (66.7%) 4 (66.7%) 14 (51.9%) 22 (81.5%)
Grade 4 heme 2 (33.3%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 3 (50.0%) 6 (22.2%) 15 (55.6%)
Grade 3+ nonhematologic 4 (66.7%) 3 (100.0%) 4 (66.7%) 1 (33.3%) 1 (33.3%) 3 (50.0%) 16 (59.3%) 12 (44.4%)
Grade 4+ nonhematologic 2 (33.3%) 2 (66.7%) 0 (0.0%) 1 (33.3%) 0 (0.0%) 0 (0.0%) 5 (18.5%) 2 (7.4%)
aAdverse events reported regardless of attribution.
bIncluded in phase II analysis.
cThe recommended phase II dose (RP2D) included six phase I patients enrolled at dose level 6 and 21 patients enrolled during the phase II portion only.
dOne grade 5 pneumonitis possibly related to treatment occurred.
DLT, dose-limiting toxicity.
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TABLE 5.  Commonly Occurring (>5%) Grade 3 of 4 Adverse Events,a Including All Grade 4 Adverse Events (by Phase of Study)
Toxicity
Grade 3 Grade 4
n (%) n (%)
Phase 1 (n = 27)
  Hematologic Leukocyte count decreased 9 (33.3%) 3 (11.1%)
Neutrophil count decreased 4 (14.8%) 6 (22.2%)
Lymphocyte count decreased 2 (7.4%) 0 (0.0%)
Platelet count decreased 2 (7.4%) 0 (0.0%)
  Nonhematologic Dyspnea 6 (22.2%) 0 (0.0%)
Dysphagia 3 (11.1%) 0 (0.0%)
Fatigue 2 (7.4%) 0 (0.0%)
Febrile neutropenia 2 (7.4%) 0 (0.0%)
Nausea 2 (7.4%) 0 (0.0%)
Pneumonitis 2 (7.4%) 0 (0.0%)
Dehydration 1 (3.7%) 1 (3.7%)
Hypotension 1 (3.7%) 1 (3.7%)
Myocardial ischemia 0 (0.0%) 2 (7.4%)
Thrombosis 0 (0.0%) 2 (7.4%)
Cardiac troponin I increased 0 (0.0%) 1 (3.7%)
Phase II RP2D (n = 27)
  Hematologic Leukocyte count decreased 13 (48.1%) 4 (14.8%)
Neutrophil count decreased 12 (44.4%) 6 (22.2%)
Platelet count decreased 2 (7.4%) 10 (37.0%)
Hemoglobin decreased 2 (7.4%) 0 (0.0%)
Lymphocyte count decreased 0 (0.0%) 1 (3.7%)
  Nonhematologic Fatigue 6 (22.2%) 0 (0.0%)
Nausea 3 (11.1%) 0 (0.0%)
Dyspnea 2 (7.4%) 1 (3.7%)
Anorexia 2 (7.4%) 0 (0.0%)
Pneumonitis 2 (7.4%) 0 (0.0%)
Syncope 2 (7.4%) 0 (0.0%)
Depressed level of consciousness 1 (3.7%) 1 (3.7%)
Serum sodium decreased 1 (3.7%) 1 (3.7%)
Myalgia 1 (3.7%) 1 (3.7%)
Serum potassium decreased 0 (0.0%) 1 (3.7%)
Hypoxia 0 (0.0%) 1 (3.7%)
aAdverse events reported regardless of attribution.
RP2D, recommended phase II dose.
TABLE 6.  Dose-intensity of Chemotherapy and the Radiotherapy Received at the Recommended Phase II Dose
Chemotherapy/RT Cycle n
% of Patients Who  
Received Full Dosea
Median % of Per Protocol 
Expected Dose (Range)
Bortezomib 1 27 85% (23 of 27) 99 (50–107)
2 24 67% (16 of 24) 98 (13–103)
Paclitaxel 1 27 100% (27 of 27) 100 (99–102)
2 24 79% (19 of 24) 100 (50–103)
Carboplatin 1 27 100% (27 of 27) 100 (100–100)
2 24 83% (20 of 24) 100 (0–100)
RTb 1–2b 27 85% (23 of 27) 100 (3–104)
aDefined as receiving at least 95% of the expected dose.
bThe target dose was 6000 cGy given in 30 daily (except weekends) fractions of 200 cGy each, starting on day 1 for a total of 6 weeks (two cycles). Most patients received the full 
RT dose and most received the 30 total fractions, as expected.
RT, radiation therapy.
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bortezomib.45 In relapsed/refractory follicular lymphoma, the 
presence of PSMB1 P11A (G allele) and low CD68 expression 
(≤50 CD68-positive cells) were found to be associated with 
improved outcome in patients treated with bortezomib–ritux-
imab versus rituximab.46 Future studies need to be conducted 
to identify predictive biomarkers for bortezomib in NSCLC to 
identify the suitable candidate for treatment with bortezomib.
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